Canada Life
PRVB

Canada Life’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Canada Life’s Portfolio PRVB Stock Details PRVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-4,618
Closed -$111K – 2328
2023
Q1 		$111K Hold
4,618
– – ﹤0.01% 1967
2022
Q4 		$49K Buy
4,618
+1,910
+71% +$15.4K ﹤0.01% 2079
2022
Q3 		$12K Hold
2,708
– – ﹤0.01% 2328
2022
Q2 		$11K Hold
2,708
– – ﹤0.01% 2354
2022
Q1 		$21K Hold
2,708
– – ﹤0.01% 2344
2021
Q4 		$15K Hold
2,708
– – ﹤0.01% 2419
2021
Q3 		$17K Hold
2,708
– – ﹤0.01% 2470
2021
Q2 		$23K Hold
2,708
– – ﹤0.01% 2464
2021
Q1 		$28K Hold
2,708
– – ﹤0.01% 2460
2020
Q4 		$46K Hold
2,708
– – ﹤0.01% 2313
2020
Q3 		$35K Hold
2,708
– – ﹤0.01% 2279
2020
Q2 		$38K Buy
+2,708
New +$34.2K ﹤0.01% 2316

Other funds holding PRVB

UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Canada Life's PRVB Position: Q2 2023 in Review

Canada Life sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 4,618 shares — an estimated $111K sold.

Canada Life first reported a position in PRVB in Q2 2020 and held it in 12 quarters. The position peaked at $111K in Q1 2023. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.

  • Canada Life reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Canada Life sold 4,618 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $111K.
  • Canada Life first reported a position in Provention Bio, Inc. Common Stock in Q2 2020 and held it in 12 quarters.
  • Canada Life's Provention Bio, Inc. Common Stock position peaked at $111K in Q1 2023.
  • 1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.

Based on Canada Life's 13F filing for Q2 2023, filed 10 Aug 2023.